Winston Dunn MD

Dr. Winston Dunn is a Professor in the Department of Internal Medicine, Division of Gastroenterology at the University of Kansas Medical Center, where he has served since 2010 and was advanced to full professor in 2025. His distinguished career initially focused on genetic determinants of fibrosis regression, innovative care strategies for Nonalcoholic Steatohepatitis (NASH), and liver recovery post-Hepatitis C, highlighted by a significant K23-funded NIH project.

Dr. Dunn's recent research has pivoted to pioneering artificial intelligence (AI) applications in hepatology. Notably, his leadership in developing AI-driven prognostic models has culminated in significant publications, including the ALCHAIN model predicting 90-day mortality in alcohol-associated hepatitis, featured prominently in Hepatology. His recent landmark study, "ALADDIN: A Machine Learning Approach to Enhance the Prediction of Significant Fibrosis or Higher in MASLD," published in the American Journal of Gastroenterology, further demonstrates his influential role in advancing clinical prognostic tools in liver disease.

In addition to his groundbreaking research, Dr. Dunn leads multiple high-profile clinical trials funded by industry leaders like Novo Nordisk, Madrigal Pharmaceuticals, and Inventiva, investigating novel therapies for NASH and liver fibrosis. His work exemplifies a remarkable fusion of clinical hepatology and cutting-edge AI technology, substantially improving diagnostics, patient outcomes, and therapeutic strategies on a global scale.